Autolus Therapeutics plc
For the period ended Mar 31, 2026. Filed May 14, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 14, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
Insider Trading Arrangements
During the three months ended March 31, 2026, none of our directors or officers (as defined in Rule 16a-1(f) under the Exchange Act)adopted orterminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as those terms are defined in Item 408(a) of Regulation S-K.
Resignation of John Berriman as Director
On May 13, 2026, Mr. John Berriman, a member of the board of directors of the Company since 2014, notified the Company of his intention not to stand for re-election at the Company’s 2026 Annual General Meeting of Shareholders. Mr. Berriman has indicated that this decision was not the result of any disagreement with the Company’s management or Board. The Company thanks Mr. Berriman for his dedicated service to the Company and wishes him well in his future endeavors.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.